Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207492 · ClinicalTrials.gov registry record · Phase 2
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
A Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Andrew J. Wagner, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 7
- Study locations
NCT01207492: Completed Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, sponsored by Andrew J. Wagner, MD, PhD.
NCT01207492 is a Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis that has completed, run by Andrew J. Wagner, MD, PhD. The registered enrollment target is 17 participants, below the 116-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01207492, a Phase 2 study of Tenosynovial Giant Cell Tumor and Pigmented Villonodular Synovitis, has completed, sponsored by Andrew J. Wagner, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 7
- Study locations
Study Summary
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
Primary Outcome
To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Conditions Studied
Interventions
- DRUG nilotinib
Study Locations (7)
California
- Sarcoma Oncology Center - Santa Monica
- Stanford University Medical Center - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Florida
- H. Lee Moffitt Cancer Center - Tampa
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
What the finished NCT01207492 record still lists
NCT01207492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 116-participant average among 8 other Tenosynovial Giant Cell Tumor trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Tenosynovial Giant Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which nilotinib is the first listed.
NCT01207492 lists 7 locations in 5 states (California, Massachusetts, Florida).
Frequently Asked Questions
What is clinical trial NCT01207492 about?
NCT01207492 is a clinical study titled "Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor". Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop t...
What is the current status of trial NCT01207492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-09. Estimated completion is 2015-08.
What conditions does trial NCT01207492 study?
This clinical trial studies the following conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor.
What interventions are being tested in trial NCT01207492?
The interventions under investigation include: nilotinib (DRUG).
Who is sponsoring clinical trial NCT01207492?
This trial is sponsored by Andrew J. Wagner, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01207492 being conducted?
This trial has 7 study locations across California, Florida, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tenosynovial Giant Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01207492's enrollment target sits among peer trials
17 9th of 8 the lowest of 8 other Tenosynovial Giant Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tenosynovial Giant Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
RECRUITING
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
RECRUITING · Phase 1
-
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
RECRUITING
-
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 3
-
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
ACTIVE NOT RECRUITING · Phase 1
-
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia